Weight gain, dyslipidaemia, hypertension common after adjuvant chemo for breast cancer
Hypertension, dyslipidaemia and an abnormal 60-percent increase in body mass index (BMI) are common complications in premenopausal breast cancer patients who have received adjuvant chemotherapy, a recent study in a Chinese population has found.
The study included 280 breast cancer patients (median age 46.5 years), of which 88 had stage I, 165 had stage II and 27 had stage III. Oestrogen receptor (ER)-positive cancers were observed in 73 percent, progesterone receptor (PR)-positive in 67 percent and HER2-positive in 17 percent.
At study entry, 63.2 percent (n=177) experienced >2 percent weight gain since breast cancer diagnosis. Of these, 121 had a weight gain of ≥5 percent.
Multivariate analysis showed that taxane-containing chemotherapies (odds ratio [OR], 2.041; 95 percent CI, 1.127 to 3.696; p=0.0186) and chemotherapy-related amenorrhoea (CRA; OR, 3.472; 1.395 to 8.621; p=0.0074) were independent factors for weight gain >2 percent.
Of the participants, 30.7 percent (n=86) were hypertensive, 13.2 percent (n=37) had elevated systolic blood pressure (SBP) and 3.9 percent (n=11) had elevated diastolic blood pressure (DBP). SBP and DBP were elevated in 13.6 percent (n=38).
Overweight or obesity at study entry (OR, 2.723; 1.568 to 4.728; p=0.0004) and ER-positivity (OR, 0.552; 0.311 to 0.980; p=0.0423) were significantly related to hypertension.
In terms of fasting serum lipid levels, 34.3 percent (n=93) had high total cholesterol, 56.1 percent (n=152) had high low-density lipoprotein cholesterol (LDL-C), 6.6 percent (n=18) had high high-density lipoprotein cholesterol (HDL-C) and 22.9 percent (n=62) had hypertriglyceridemia.
Overweight or obesity at study entry was a consistent significant factor for high total cholesterol (OR, 1.764; 1.013 to 3.073; p=0.0451), high LDL-C (OR, 2.560; 1.410 to 4.649; p=0.0020), high HDL-C (OR, 7.786; 1.742 to 34.795; p=0.0072) and high triglyceride (OR, 2.775; 1.446 to 5.325; p=0.0021).